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Objective: The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-
reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).
Methods: We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in mono-
therapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinor-
rhoea, sneezing, nasal itching), ocular symptoms (redness/pufﬁness, watery eyes), and other PROs (olfactory dysfunction,
difﬁculty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. The
following clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), Total
Symptom Score of Patient-Reported Outcomes (TSS-PROs), and a Composite Symptoms Score (CSS). Patients were classiﬁed as
responders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkers
in nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power ﬁeld), eotaxin-1 and eotaxin-2.
Results: After treatment, signiﬁcant reductions were observed for all the symptom scores. Forty-two of 78 patients were con-
sidered responders. A signiﬁcant reduction of eosinophils in nasal mucosa and of levels of eotaxin-1 and eotaxin-2 in nasal lavage
were observed after treatment in responder patients. Patients with asthma had an increased probability to be responders.
Conclusion: NARES patients may beneﬁt from treatment with montelukast. In particular, the presence of concomitant
asthma may be predictive of a greater efﬁcacy.
Key Words: NARES, asthma, antileukotrienes, montelukast, eosinophils, eotaxin, precision medicine.
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INTRODUCTION
Cysteinyl-leukotrienes (cysLTs), including LTC4,
LTD4, and LTE4, are proinﬂammatory mediators derived
from arachidonic acid and synthesized by mast cells and
eosinophils in response to stimuli such as allergens, proin-
ﬂammatory cytokines, and other types of receptor-
dependent stimuli.1 After release into the circulation,
cysLTs reach their targets in the upper and lower airways
and interact with two main receptors (LT1R and LT2R), eli-
citing a number of responses including the recruitment of
inﬂammatory cells (particularly eosinophils), cytokine
release, enhanced mucus production, mucosal edema, and
activation of airway smooth muscle. Most of the proinﬂam-
matory activity seems to be attributed to mediation through
LT1R, which are expressed on basophils; mast cells; den-
dritic cells; eosinophils; monocytes/macrophages; and a vari-
ety of structural cells such as airway smooth muscle,
ﬁbroblasts, epithelial, and endothelial cells.2
Clinical studies3,4 have shown that LT1R selective
antagonists such as montelukast and zaﬁrlukast may be
advantageously administered orally in patients with lower
airway inﬂammation/bronchial obstruction or reactivity due
to the reduction of eosinophil accumulation and inﬁltration
in the bronchial wall. A recent meta-analysis suggests that,
although inhaled corticosteroids remain the ﬁrst-line treat-
ment, leukotriene receptor antagonists in monotherapy sig-
niﬁcantly reduce severe exacerbations in chronic mild to
moderate asthma.5 The effectiveness of antileukotrienes has
also been assessed in patients suffering from allergic rhinitis
(AR) with or without concomitant asthma. The common out-
come of studies in this ﬁeld was the signiﬁcant improvement
in daytime and nighttime symptoms related to both peren-
nial and seasonal AR in patients treated with montelukast
in comparison to placebo.6,7
Currently, the effects of montelukast on symptomatic
patients with nonallergic rhinitis (NAR), and in particular
on NAR with eosinophilic syndrome (NARES), have not
been investigated in the literature. Nonallergic rhinitis
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includes an extensive list of different phenotypes that differ
in terms of pathogenic mechanisms and clinical features.8–10
Several authors11–16 have encouraged the detection of
inﬂammation in patients affected by NAR because the type
of inﬂammatory pattern may impact differently both the dis-
ease severity and therapeutic response. Therefore, we
strongly suggest deﬁning the different phenotypes of NAR,
and in particular the presence of nasal eosinophilia, which
causes the most severe symptoms and greater association
with comorbidities.17,18 Corticosteroids are effective in con-
trolling nasal symptoms in these patients by directly induc-
ing eosinophil apoptosis, inhibiting eosinophil recruitment
and its migration into the nasal airways.19 Nevertheless, the
long-term usage of corticosteroids is limited in certain situa-
tions such us hemorrhagic diatheses, history of recurrent
nasal bleeding, and ocular contraindications; for these, alter-
native therapeutical options may be useful.
Because cysLTs are produced by eosinophils and
play an important role in eosinophilic inﬂammation,
selective antagonists such as montelukast may represent
an alternative option to control nasal symptoms in
NARES patients. Nonetheless, there are no existing pub-
lished studies examining the role of leukotriene modiﬁers
in the treatment of NARES. Because LT1R antagonists
have been shown to be effective in attenuating eosino-
philic inﬂammation in the airways of asthmatic subjects
and in the nasal mucosa of allergic subjects, we hypothe-
sized that this drug could have a signiﬁcant effect on the
treatment of eosinophilic NAR patients.
The aim of our study was to analyze the effectiveness
of montelukast, an LT1R selective antagonist, in the man-
agement of nasoocular symptoms and PROs in patients
with NARES. In addition, secondary objectives were to
assess the effect of montelukast on nasal eosinophilic inﬁl-
tration and eosinophilic biomarkers in nasal lavage while
phenotyping NARES responder patients based on therapeu-
tic response.
MATERIALS AND METHODS
Study Population and Study Design
This is a prospective open-label cohort study (therapeutic)
of level 2. Symptomatic patients with a diagnosis of NARES were
recruited and treated with 10 mg montelukast orally in mono-
therapy once a day for 8 weeks. Patients were followed between
February 2018 and April 2018 at our rhinology unit of the head
and neck department of A. Gemelli Hospital Foundation IRCCS
(Institute of Treatment and Scientiﬁc Research). All the patients
gave their informed consent to participate in the study. The
study was approved by the ethics committee of our institution
(ID1805).
Montelukast was safely tolerated: 78 of 80 patients com-
pleted the treatment period (53 females [67.9%]; mean age of
41 ± 14 years). Baseline characteristics of patients are shown in
Table I. There were only two dropouts in total, and the reasons
for discontinuation were minor adverse events (headache in one
patient, gastrointestinal symptoms in another).
Inclusion criteria. The phenotyping of NARES patients
was based on several inclusion and exclusion criteria. Inclusion
criteria consisted of clinical symptoms of persistent rhinitis, neg-
ative skin prick test, negative speciﬁc IgE blood assays with
Radioallergosorbent test (RAST), negative intranasal allergen
provocation test for principal inhalant allergens (including house
dust mites, major Italian pollens, mold, dogs/cats epithelium),
and eosinophilic inﬁltration in the sinonasal mucosa detected by
nasal cytology greater than 20% of total inﬂammatory cells in at
least 10 ﬁelds observed (diagnostic cutoff assumed by most
authors in literature).17,18
Exclusion criteria. We excluded from the study patients
presenting at least one of these conditions: Previous sinonasal
surgery, local or systemic medical treatment such as intranasal
or oral corticosteroid (during the previous 4 weeks), positive skin
prick test, negative nasal cytology or eosinophil inﬁltration lower
than the assumed diagnostic cutoff, evidence of nasal polyps at
nasal endoscopy (Meltzer endoscopic score > 0),20 or evidence of
sinonasal occupancy at computed tomography scan (Lund-
Mackay score > 0).21
Efﬁcacy Outcomes
Nasal symptoms and patient-reported outcomes.
Patients were asked to complete a rhinological questionnaire at
baseline and at end of treatment to score, using a visual analogi-
cal scale (VAS) ranging from 0 to 10 cm, their main nasal symp-
toms (nasal obstruction, rhinorrhoea, sneezing, and nasal
itching); ocular symptoms (redness/pufﬁness, watery eyes); and
other PROs such as olfactory dysfunction, sleeping difﬁculties,
nighttime awakenings, and nasal congestion on awakening. For
each symptom, the patients had to indicate, using a scale rang-
ing from 0 to 10, their answer to the question: “How troublesome
is your symptom?” Patients were notiﬁed that 0 indicated
“absence of symptom” and 10 indicated “symptom extremely
bothersome.” For each patient, we calculated the T4NSS by add-
ing the scores of the four main nasal symptoms, the T2OSS by
adding the scores of the two main ocular symptoms, and the
TSS-PROs by adding the scores of the other four PROs (olfactory
dysfunction, difﬁculty going to sleep, nighttime awakenings, and
nasal congestion on awakening). Finally, the CSS was also calcu-
lated by adding the T4NSS, T2OSS, and TSS-PROs scores. The
efﬁcacy was assessed comparing values of symptom scores at
baseline and at the end of 8 weeks of treatment. Patients were
classiﬁed as responders to treatment when there was at least
50% improvement in the CSS compared to baseline. We lastly
performed uninominal logistic regression analysis based on clini-
cal patient phenotypes (familiar history for sinonasal eosino-
philic inﬂammation, associated asthma, and blood
hypereosinophilia) to establish the relative risk (RR) of good
response to the therapy.
Eosinophilic inﬁltration of nasal mucosa by nasal
cytology. Nasal leukocyte counts were performed on scraped
nasal tissue, obtained from the inferior turbinate bilaterally.
Scraping was performed using Rhinoprobe (Farmark s.n.c,
Milan, Italy). The sample was gently spread on glass slides and
immediately ﬁxed in 95% ethyl alcohol and stained with May-
Grünwald-Giemsa. The slides were examined under oil immer-
sion by light microscopy at a magniﬁcation of ×1000. Nasal tis-
sue eosinophil inﬁltration was measured as eosinophil count per
high power ﬁeld (Ec-hpf ), and reported as the mean of at least
10 high-powered ﬁelds observed at nasal cytology.3,12,13,17,18
Nasal lavage ﬂuid collection and processing of eosino-
philic biomarkers. Nasal lavage ﬂuid was obtained from sub-
jects with the head bent down, based on methods previously
described.22 Each nostril was washed by instilling 5 mL of saline
solution (NaCl 0.9%) prewarmed to 35 C. The ﬂuid was collected
by asking the subjects to lean forward and blow the nasal
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contents gently into a funnel connected to a 30 mL universal con-
tainer. The lavage ﬂuid was ﬁltered to remove any nasal mucus,
centrifuged immediately at 4 thousand rpm for 5 minutes, and
then divided into aliquots and frozen at −80C until assay.
CCL24 (eotaxin-2) and CCL11 (eotaxin-1) immunoas-
say. CCL24 and CCL11 were assayed according to the manufac-
turer’s instructions (R&D Systems, Minneapolis, MN) by
Quantikine Human CCL24 and CCL11 Immunoassay ELISA
kits designed to measure CCL24 and CCL11 levels in cell culture
supernatant, serum, and plasma. All samples, standards, and
controls were assayed in duplicate, and mean values were calcu-
lated as in our previous experience.23,24 The coefﬁcient of varia-
tion of duplicates was always less than 7%. The sensitivity of the
CCL24 assay was 2.5 pg/mL, and the range was from 2.5 to
2,500 pg/mL. The sensitivity of the CCL11 assay was 5.0 pg/mL,
and the measuring range was from 5.0 to 1,000 pg/mL.
Statistical Analysis
Statistical analysis was performed using SPSS package ver-
sion 22.0 (IBM Corp., Armonk, NY). Baseline and posttreatment
scores were compared by two-tailed Student t test for paired
data. The limit for statistical signiﬁcance was set at alpha = 0.05
because the P value < 0.05 was considered signiﬁcant. The RR of
good outcome (probability to be a responder to montelukast
treatment) was established for clinical factors by binominal
regression analyses. In our study, we chose to perform a binomial
logistic regression because the dependent variable was dichoto-
mous. The outcome was coded as “0” or “1,” leading to the most
straightforward interpretation. In our series, “1” represents
responder to treatment, “0” represents nonresponder to treatment.
The results were considered signiﬁcant for a P value < 0.05.
RESULTS
Efﬁcacy Outcomes
Symtpoms control. In Figure 1, we report the values
of mean VAS scores for nasal symptoms, eye symptoms,
and patient’s reported outcomes in all patients before and
after treatment. We observed a signiﬁcant reduction in
all mean scores after treatment for each item analyzed
(P < 0.05). Furthermore, we identiﬁed a signiﬁcant
decrease in mean T4NSS (Fig. 1A) (from 26.0 ± 8.0 to
12.8 ± 5.4, P < 0.05) in mean T2OSS (Fig. 1B) (from
8.3 ± 4.1 to 2.7 ± 1.5, P < 0.05) and in mean TSS-PROs
(Fig. 1C) (from 11.8 ± 4 to 4.6 ± 3, P < 0.05). Finally, a
signiﬁcant decline of the mean value of CSS from
46.0 ± 15.6 to 20.3 ± 15.2 (P < 0.05) was ascertained. In
evaluating the efﬁcacy of montelukast for individual
patients, 42 of 78 patients (53.8%) were considered
responders, whereas 36 of 78 patients (46.2%) did not
have good control of symptoms and were considered non-
responders. We did not ﬁnd a signiﬁcant difference
between responders and nonresponders in terms of
median age and gender ratio.
Eosinophilic inﬁltration of nasal mucosa. A signiﬁ-
cant difference between mean Ec-hpf before and after
treatment was observed in all patients (54.1 ± 8.1
vs. 42.3 ± 7.1, P < 0.05), especially in responders
(65.9 ± 10.2 vs. 33.5 ± 8.4, P < 0.05), as shown in
Figure 2. No differences were found in nonresponders
before and after treatment (43.9 ± 8.1 vs. 51.7 ± 9.9).
Eosinophilic biomarkers in nasal ﬂuid pre- and post-
treatment. Although eotaxin-1 concentrations in nasal
lavage were unchanged after montelukast treatment
(22.8 ± 6.1 pg/mL vs. 23.4 ± 6.9 pg/mL), a signiﬁcant reduc-
tion (29.1 + 8.5 pg/mL vs. 19.9 ± 8.1 pg/mL, P < 0.05) was
observed in responders, whereas no considerable changes
were observed in nonresponders (21.1 ± 7.5 pg/mL
vs. 29.6 ± 8.1 pg/mL) (Fig. 3). Similar ﬁndings account for
eotaxin-2 concentration, a signiﬁcant decrease in responders
(145.6 + 19.5 pg/mL vs. 115.4 + 18.1 pg/mL, P < 0.05) but
no difference in nonresponders (126.6 + 20.5 pg/mL
vs. 145.8 + 21.5 pg/mL) or in the overall population
(136.6 ± 23.2 pg/mL vs. 134.6 ± 22.4 pg/mL) (Fig. 4).
Phenotyping of NARES Patients Based on
Treatment Response
Distribution of clinical conditions commonly associ-
ated with nonallergic eosinophilic rhinitis is reported in
Table I. We evaluated the RR of good response to
TABLE I.
Clinical Characteristics and Eosinophilic Biomarkers of Patients at Baseline
All Patients N = 78 Responders N = 42 No Responders N = 36 P Value
Age, years (mean ± SD) 41 ± 14 40 ± 13 42 ± 15 > 0.05
Gender (females) 53 (67.9%) 28 (66.7%) 25 (69.4%) > 0.05
Clinical factors
Family history of sinonasal disorders 30 of 78 (38.5%) 14 of 42 (33.3%) 16 of 36 (44.4%) > 0.05
Duration of rhinitis, years (mean ± SD) 7.2 ± 3.0 6.1 ± 3.0 8.2 ± 2.0 > 0.05
Asthma 22 of 78 (28.2%) 15 of 42 (35.7%) 7 of 36 (19.4%) < 0.05
Peripheral blood ipereosinophilia 22 of 78 (28.2%) 10 of 42 (23.8%) 12 of 36 (19.0%) > 0.05
Eosinophilic biomarkers
Eosinophils, Ec-hpf (mean ± SD) 54.1 + 8.1 65.9 ± 10.2 43.9 ± 8.1 < 0.05
Eotaxin-1, pg/mL (mean ± SD) 22.8 + 6.1 29.1 + 8.5 21.1 ± 7.5 > 0.05
Eotaxin-2, pg/mL (mean ± SD) 136.6 + 23.2 145.6 + 19.5 126.6 + 20.5 > 0.05
P values of comparison between responder and nonresponder are reported.
SD = standard deviation.
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treatment in the presence of asthma, blood hypereosino-
philia, and family history of eosinophilic sinonasal inﬂam-
mation using binominal logistic regression analyses.
Patients with asthma showed an increased probability of a
good outcome (RR: 1.59 [1.05–2.41], P < 0.05), whereas a
nonsigniﬁcant risk was observed for both blood hypereosi-
nophilia (RR: 0.90 [0.48–1.33]) and family history of rhini-
tis (RR: 0.80 [0.51–1.26]) (Fig. 5).
DISCUSSION
Several studies25,26 have demonstrated that leukotri-
ene receptor antagonists may inhibit bronchoconstriction
and attenuate eosinophilia in the lower airway mucosa of
asthmatic patients. Moreover, over the years montelukast
has become the object of controlled clinical trials evaluating
its efﬁcacy and safety in the treatment of AR with or with-
out concomitant asthma. Consequently, it has been
Fig. 1. Severity of nasal-ocular symptoms and PROs before and after montelukast treatment in nonallergic rhinitis eosinophilic syndrome
patients: (A) nasal symptoms, (B) Patient-Reported Outcomes (PROs), and (C) Eye Symptoms.
Fig. 2. Nasal mucosa eosinophil inﬁltration (Ec-hpf ) before and after montelukast treatment in nonallergic rhinitis eosinophilic syndrome
patients: all patients, responders, and nonresponders.Ec-hpf = eosinophilc count per high power ﬁeld.
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approved by the U.S. Food and Drug Administration for the
treatment of both seasonal and perennial AR.27 It is well
known that cysLTs are synthesized via 5-lipoxygenase
metabolism of arachidonic acid by mast cells and basophils
during the AR early phase in response to antigens, and by
eosinophils and macrophages during the AR late phase.
Studies on murine experimental AR model have demon-
strated a signiﬁcant decrease in the number of eosinophils
in nasal mucosa after treatment with montelukast not only
by a reduction in tissue recruitment but also as a result of
limited eosinophilopoiesis that is IL-5 dependent, with
effects on several stages of cellular differentiation and
maturation.28
In 2010, Mullol et al.29 investigated the anti-
inﬂammatory effects of montelukast in an in vitro model of
upper-airway eosinophil inﬂammation and demonstrated
the reduction of proinﬂammatory cytokines from nasal
mucosa and polyp epithelial cells, as well as lower eosino-
phil survival primed by epithelial cell secretions. Montelu-
kast had a strong inhibitory effect on Fetal Bovine Serum
(FBS) -induced GM-CSF, IL-6, and IL-8 secretion but not
on ICAM-1. These anti-inﬂammatory effects on epithelial
cell cytokine secretion and on eosinophil survival suggest
that montelukast may contribute to the reduction of eosino-
philic inﬂammation in upper-airway inﬂammatory diseases
such as rhinitis and nasal polyposis.30
In contrast to the extensive amount of information
found in the literature on AR, there is limited data on the
treatment of NAR,8 for which the intense symptoms can
negatively affect the patient’s quality of life. Our prelimi-
nary results suggest for the ﬁrst time that some NARES
patients may signiﬁcantly beneﬁt from treatment with
Fig. 3. Eotaxin-1 (A) and eotaxin-2 (B) levels (pg/dl) before and after montelukast treatment in nonallergic rhinitis eosinophilic syndrome
patients: all patients, responders, and nonresponders.
Fig. 4. Eotaxin-2 levels (mean values in pg/dl) in nasal lavage before and after montelukast treatment in nonallergic rhinitis eosinophilic syn-
drome patients: all patients, responders, and nonresponders.
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montelukast 10 mg once a day. Considering all the patients
enrolled, we observed a signiﬁcant improvement of scores of
nasal symptoms, eye symptoms, and PROs, with a signiﬁ-
cant reduction in the percentage of eosinophilic inﬁltration
in the sinonasal mucosa following treatment. Analyzing the
efﬁcacy of montelukast in single patients, we observed a
decrease of at least 50% of the CSS in approximately half of
the treated patients, who were considered responders. In
responder but not in nonresponder NARES patients, we
also observed a signiﬁcant reduction of eosinophil inﬁltra-
tion into the nasal mucosa. In this series, montelukast
showed a good safety proﬁle with the absence of any severe
side effects, as also demonstrated in previous studies.25,26
We conﬁrmed good patient compliance and good tolerance
to montelukast for 8 weeks in most of the patients and only
minor side effects in two patients (headache and gastroin-
testinal symptoms).
Many studies23,24,31 have shown that the measure-
ment of chemokine levels in nasal secretions may be use-
ful in evaluating the degree of chronic nasal
inﬂammation and consequently the response to therapy.
Peric et al.32 observed that nasal secretion levels of cer-
tain chemokines (MCP-1, MCP-3, and RANTES) corre-
lated with nasal symptoms and degree of eosinophilia in
patients with NARES and perennial AR. Similarly, we
have previously demonstrated an important correlation
with the levels of eotaxins and degree of eosinophilia and
clinical symptoms in eosinophilic patients.23,24 In the pre-
sent series, we have observed that the levels of eosino-
philic biomarkers were modiﬁed according to outcomes.
After treatment, we observed signiﬁcantly lower levels of
eotaxin-1 and eotaxin-2 in responders, whereas an
increasing trend was observed in nonresponders, although
the difference did not reach statistical signiﬁcance. These
results were congruent with nasal mucosa eosinophil inﬁl-
tration data. The evaluation of these objective parameters
partially excluded a placebo effect in our series because
we observed a signiﬁcant reduction of eosinophilic bio-
markers only in responders. The placebo effect could
potentially have some impact on the improvement of sub-
jective outcomes (PROs, symptoms, VAS), whereas it is
difﬁcult to explain its effect on objective outcomes (eosino-
philic biomarkers). Recent reviews on placebo effects in
clinical trials suggest that objective changes following pla-
cebo treatments may not exist, or at least have been con-
siderably overestimated. Meissner et al.33 concluded in a
review of clinical trials that placebo interventions can
improve physical disease processes of peripheral organs
more easily and effectively than biochemical processes.
Analyzing the response to therapy based on associ-
ated clinical factors, it was possible to identify different
subgroups of patients who were presumed to belong to
different phenotypes. Patients with asthma were the best
responders to monotherapy with montelukast. Logistic
regression analyses showed that they had an increased
probability of good response to treatment with an RR of
1.59 (P < 0.05). These results are in concordance with
previous studies in which montelukast treatment was
reported to be of greater beneﬁt in patients with asthma
associated with rhinitis or rhinosinusitis.34,35 Philip
et al.36 observed that patients with AR beneﬁted the most
from montelukast treatment (based on global evalua-
tions) and achieved the greatest improvement for asth-
matic patients. Yazici et al.37 studied the effects of
montelukast in patients affected by nasal polyposis with
a history of asthma. They observed an improvement of
Rhinosinusitis Disability Index scores with montelukast
in association with intranasal corticosteroids within this
patient population. The ﬁndings of our study seem to fol-
low a similar direction, suggesting that antileukotrienes
may be useful to treat other multimorbidies such as
NARES + asthma.
CONCLUSION
Our data suggest that, for the ﬁrst time it has been
demonstrated that montelukast may be an effective treat-
ment option in patients affected by NARES to control
their nasal and ocular symptoms, as well as other disease
PROs such as olfactory dysfunction and nighttime distur-
bances. We also observed a signiﬁcant reduction of nasal
mucosa eosinophil inﬁltration and biomarkers (eotaxin)
in responders compared to nonresponder patients.
Finally, according to the emerging need for proper pheno-
typing of chronic rhinitis patients, going towards a preci-
sion medicine approach,38 we identiﬁed different subgroups
of NARES patients based on the response to antileuko-
triene treatment. Interestingly, the presence of concomi-
tant asthma may be considered a predictive factor for
montelukast efﬁcacy. This is the ﬁrst study in the literature
demonstrating any efﬁcacy of antileukotrienes on NARES
patients. Unfortunatly, this is an open-label nonplacebo
controlled trial and that is the main limitation of our study.
Based on the present study, future randomized placebo-
controlled trials are nonetheless needed to conﬁrm the efﬁ-
cacy and tolerability of antileukotrienes in eosinophilic
NAR patients, especially in those with concomitant
asthma, and potentially in comparison with standard treat-
ments such as intranasal corticosteroids.
Fig. 5. Foster plot showing RR of good response to montelukast
treatment based on clinical characteristics of nonallergic rhinitis
eosinophilic syndrome patients. Clinical factors analyzed and RR
with 95% conﬁdence interval are showed.RR = relative risk.
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